Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens

Leukemia & Lymphoma
Paola TacchettiElena Zamagni

Abstract

We retrospectively investigated the role of serial serum-free light chain (sFLC) evaluations in 150 multiple myeloma (MM) patients treated with first-line bortezomib-based regimens. Baseline sFLC ratio (sFLCR) identified three groups of patients - normal, lightly abnormal (<100), and highly abnormal (≥100) - with different progression-free survival (PFS: 3-year estimate 72% versus 61% versus 44%, respectively, p = 0.03). Moreover, the achievement of a normal sFLCR correlated with extended PFS (49 versus 17 months, p < 0.0001) and overall survival (75 versus 43 months, p < 0.0001) as compared with abnormal sFLCR, a gain maintained in a multivariate analysis for PFS. At relapse, a high sFLCR was associated with earlier start of salvage therapy compared with sFLCR <100 (3-month probability: 89% versus 64%, p = 0.0426). In 20% of patients, sFLC escape preceded the conventional relapse by a median of 3.8 months. Our results highlight the role of sFLC assay in the prognosis and follow-up of MM.

References

Jan 17, 2003·Mayo Clinic Proceedings·Robert A KylePhilip R Greipp
Feb 14, 2003·Lancet·Arthur R BradwellMark T Drayson
Jul 20, 2004·British Journal of Haematology·G P MeadA R Bradwell
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Apr 6, 2007·British Journal of Haematology·Marie-Christine KyrtsonisGerassimos A Pangalis
Jul 26, 2007·Haematologica·Michael John AyliffeGareth John Morgan
Mar 28, 2008·Blood·Angela DispenzieriPhilip R Greipp
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Oct 3, 2009·Leukemia·R FonsecaUNKNOWN International Myeloma Working Group
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher A Chanan-Khan, Sergio Giralt
Mar 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruno PaivaJesus F San Miguel
Nov 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Prashant KapoorMorie A Gertz
Jun 20, 2015·Blood·Joaquín Martínez-LópezUNKNOWN Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative

❮ Previous
Next ❯

Citations

Nov 11, 2018·Blood Cancer Journal·Paul G RichardsonKenneth C Anderson
Sep 25, 2021·Journal of Hematology & Oncology·Craig T Wallington-Beddoe, Rachel L Mynott

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.